Literature DB >> 21069678

Fraction size in radiation treatment for breast conservation in early breast cancer.

Melissa L James1, Margot Lehman, Phil N Hider, Mark Jeffery, Brigid E Hickey, Daniel P Francis.   

Abstract

BACKGROUND: Shortening the duration of radiation therapy would benefit women with early breast cancer treated with breast conserving surgery. It may also improve access to radiation therapy by improving efficiency in radiation oncology departments globally. This can only happen if the shorter treatment is as effective and safe as conventional radiation therapy. This is an updated version of the original Cochrane Review published in Issue 3, 2008.
OBJECTIVES: To determine the effect of altered radiation fraction size on outcomes for women with early breast cancer who have undergone breast conserving surgery. SEARCH STRATEGY: We searched the Cochrane Breast Cancer Group Specialised Register, MEDLINE, EMBASE and the WHO ICTRP search portal to June 2009, reference lists of articles and relevant conference proceedings. We applied no language constraints. SELECTION CRITERIA: Randomised controlled trials of unconventional versus conventional fractionation in women with early breast cancer who had undergone breast conserving surgery. DATA COLLECTION AND ANALYSIS: The authors performed data extraction independently, with disagreements resolved by discussion. We sought missing data from trial authors. MAIN
RESULTS: Four trials reported on 7095 women. The women were highly selected: tumours were node negative and 89.8% were smaller than 3 cm. Where the breast size was known, 87% had small or medium breasts. The studies were of low to medium quality. Unconventional fractionation (delivering radiation therapy in larger amounts each day but over fewer days than with conventional fractionation) did not affect: (1) local recurrence risk ratio (RR) 0.97 (95% CI 0.76 to 1.22, P = 0.78), (2) breast appearance RR 1.17 (95% CI 0.98 to 1.39, P = 0.09), (3) survival at five years RR 0.89 (95% CI 0.77 to 1.04, P = 0.16). Acute skin toxicity was decreased with unconventional fractionation: RR 0.21 (95% CI 0.07 to 0.64, P = 0.007). AUTHORS'
CONCLUSIONS: Two new studies have been published since the last version of the review, altering our conclusions. We have evidence from four low to medium quality randomised trials that using unconventional fractionation regimens (greater than 2 Gy per fraction) does not affect local recurrence, is associated with decreased acute toxicity and does not seem to affect breast appearance or late toxicity for selected women treated with breast conserving therapy. These are mostly women with node negative tumours smaller than 3 cm and negative pathological margins. Long-term follow up (> 5 years) is available for a small proportion of the patients randomised. Longer follow up is required for a more complete assessment of the effect of altered fractionation.

Entities:  

Mesh:

Year:  2010        PMID: 21069678     DOI: 10.1002/14651858.CD003860.pub3

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  11 in total

1.  AGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011.

Authors:  Christoph Thomssen; Anton Scharl; Nadia Harbeck
Journal:  Breast Care (Basel)       Date:  2011-08-30       Impact factor: 2.860

2.  AGO Recommendations for Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2013.

Authors:  Anton Scharl; Christoph Thomssen; Nadia Harbeck; Volkmar Müller
Journal:  Breast Care (Basel)       Date:  2013-06       Impact factor: 2.860

3.  Accelerated partial breast irradiation compared with whole breast radiation therapy: a breast cancer cohort study measuring change in radiation side-effects severity and quality of life.

Authors:  M Pérez; M Schootman; L E Hall; D B Jeffe
Journal:  Breast Cancer Res Treat       Date:  2017-01-28       Impact factor: 4.872

Review 4.  Current role of modern radiotherapy techniques in the management of breast cancer.

Authors:  Gokhan Ozyigit; Melis Gultekin
Journal:  World J Clin Oncol       Date:  2014-08-10

5.  Quality of life over time in women diagnosed with ductal carcinoma in situ, early-stage invasive breast cancer, and age-matched controls.

Authors:  D B Jeffe; M Pérez; Y Liu; K K Collins; R L Aft; M Schootman
Journal:  Breast Cancer Res Treat       Date:  2012-04-08       Impact factor: 4.872

Review 6.  Hypofractionated Radiotherapy as Adjuvant Treatment in Early Breast Cancer. A Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Wilfried Budach; Edwin Bölke; Christiane Matuschek
Journal:  Breast Care (Basel)       Date:  2015-08-19       Impact factor: 2.860

7.  Comparison of Acute and Late Toxicity of Two Regimens of 3- and 5-Week Concomitant Boost Prone IMRT to Standard 6-Week Breast Radiotherapy.

Authors:  Shahzad Raza; Stella C Lymberis; Raquel Ciervide; Deborah Axelrod; Maria Fenton-Kerimian; Chiara Magnolfi; Barry Rosenstein; J Keith Dewyngaert; Silvia C Formenti
Journal:  Front Oncol       Date:  2012-05-08       Impact factor: 6.244

8.  DEGRO practical guidelines: radiotherapy of breast cancer I: radiotherapy following breast conserving therapy for invasive breast cancer.

Authors:  F Sedlmayer; M-L Sautter-Bihl; W Budach; J Dunst; G Fastner; P Feyer; R Fietkau; W Haase; W Harms; R Souchon; F Wenz; R Sauer
Journal:  Strahlenther Onkol       Date:  2013-10       Impact factor: 3.621

9.  Factors modifying the risk for developing acute skin toxicity after whole-breast intensity modulated radiotherapy.

Authors:  Sofie De Langhe; Thomas Mulliez; Liv Veldeman; Vincent Remouchamps; Annick van Greveling; Monique Gilsoul; Eline De Schepper; Kim De Ruyck; Wilfried De Neve; Hubert Thierens
Journal:  BMC Cancer       Date:  2014-09-25       Impact factor: 4.430

10.  Hypofractionated Simultaneous Integrated Boost Radiotherapy Versus Conventional Fractionation Radiotherapy of Early Breast Cancer After Breast-Conserving Surgery: Clinical Observation and Analysis.

Authors:  Jinling Dong; Ya Yang; Dan Han; Qian Zhao; Chengxin Liu; Hongfu Sun; Zhongtang Wang; Haiqun Lin; Wei Huang
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.